ReviewUnited European gastroenterology journal2025
Global Inflammatory Bowel Disease: Opportunities and Challenges for a New Era.
Review in United European gastroenterology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Unraveling gene interaction networks in colorectal cancer and inflammatory bowel disease via a novel hybrid radial basis function network.Scientific reports · 2026Article
- Central Nervous System Involvement in Inflammatory Bowel Disease: A Bibliometric Analysis of Collaboration, Hotspots, and Research Trends.Journal of inflammation research · 2026Article
- Evaluation of electroacupuncture acupoint selection's potential in the treatment of inflammatory bowel disease: an investigation using a mouse gut microbiome and metabolomics model.Frontiers in cellular and infection microbiology · 2026Article
- Global Inflammatory Bowel Disease: Opportunities and Challenges for a New Era.United European gastroenterology journal · 2025Review
- Optimization of the HS-GC/MS technique for urine metabolomic profiling.Biology methods & protocols · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory Bowel Disease (IBD) has become a global disease. The increasing incidence of inflammatory bowel disease across the world is challenging the traditional view of IBD as a western disease and represents a unique opportunity to gain an understanding of the disease in diverse ethnic groups and in different socio-economical and geographical environments. However, the continued growth in prevalence in developing countries in the coming years will lead to increased use of health-care resources due to IBD-related complications, costs of drugs and indirect health costs. Here we analyze the challenges and opportunities that this situation represents and suggest actions and potential solutions to improve the quality of IBD care globally.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.